Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages 3555-3561

  Konstantinopoulos, Panagiotis A ^a   Spentzos, Dimitrios ^a   Karlan, Beth Y ^a   Taniguchi, Toshiyasu ^a   Fountzilas, Elena ^a   Francoeur, Nancy ^a   Levine, Douglas A ^a   Cannistra, Stephen A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; GLUTATHIONE TRANSFERASE; HISTONE DEACETYLASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RAD51 PROTEIN; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; EXONUCLEASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLATINUM DERIVATIVE; RAD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CLINICAL FEATURE; CLONE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; EPITHELIAL OVARIAN CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NEOPLASM; OVARY TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EXONUCLEASES; FEMALE; GENE EXPRESSION PROFILING; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; TREATMENT OUTCOME;

EID: 77955894453     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.5719     Document Type: Article

References (46)

1. D'Andrea AD, Grompe M: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3:23-34, 2003
2. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCAassociated ovarian carcinoma. Cancer 97:2187-2195, 2003 (Pubitemid 36444059)
3. Cannistra SA: Cancer of the ovary. N Engl J Med 351:2519-2529, 2004
4. Tan DS, Rothermundt C, Thomas K, et al: "BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530-5536, 2008
5. McCabe N, Turner NC, Lord CJ, et al: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109-8115, 2006 (Pubitemid 44299177)
6. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005 (Pubitemid 40559006)
7. Brody LC: Treating cancer by targeting a weakness. N Engl J Med 353:949-950, 2005
8. Jagtap P, Szabó C: Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421-440, 2005 (Pubitemid 40704125)
9. Ratnam K, Low JA: Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 13:1383-1388, 2007 (Pubitemid 46450426)
10. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
11. Audeh MW, Penson RTF M, Friedlander M, et al: Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCAdeficient advanced ovarian cancer. J Clin Oncol 27:277s, 2009 (suppl; abstr 5500)
12. Pal T, Permuth-Wey J, Betts JA, et al: BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807-2816, 2005 (Pubitemid 41798292)
13. Boyd J: Specific keynote: Hereditary ovarian cancer - What we know. Gynecol Oncol 88:S8-S10, 2003; discussion S11-S13
14. Risch HA, McLaughlin JR, Cole DE, et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694-1706, 2006 (Pubitemid 44942707)
15. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004
16. Teodoridis JM, Hall J, Marsh S, et al: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967, 2005 (Pubitemid 41377387)
17. Baldwin RL, Nemeth E, Tran H, et al: BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res 60:5329-5333, 2000
18. Geisler JP, Hatterman-Zogg MA, Rathe JA, et al: Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94:61-67, 2002 (Pubitemid 34082844)
19. Esteller M, Silva JM, Dominguez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569, 2000 (Pubitemid 30212318)
20. Hennessy B, Timms K, Carey MS, et al: Somatic BRCA status in ovarian tumors. J Clin Oncol 27:284s, 2009 (suppl; abstr 5528)
21. Foster KA, Harrington P, Kerr J, et al: Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 56:3622-3625, 1996 (Pubitemid 26271999)
22. Hilton JL, Geisler JP, Rathe JA, et al: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94:1396-1406, 2002 (Pubitemid 35154144)
23. Taniguchi T, Tischkowitz M, Ameziane N, et al: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568-574, 2003 (Pubitemid 36597103)
24. Hughes-Davies L, Huntsman D, Ruas M, et al: EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115:523-535, 2003 (Pubitemid 37506042)
25. Konstantinopoulos PA, Spentzos D, Cannistra SA: Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 5:577-587, 2008
26. Spentzos D, Levine DA, Kolia S, et al: Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23:7911-7918, 2005 (Pubitemid 46657390)
27. Spentzos D, Levine DA, Ramoni MF, et al: Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22:4700-4710, 2004
28. Jazaeri AA, Yee CJ, Sotiriou C, et al: Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94:990-1000, 2002 (Pubitemid 34814728)
29. Sakai W, Swisher EM, Karlan BY, et al: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116-1120, 2008 (Pubitemid 351317449)
30. Swisher EM, Sakai W, Karlan BY, et al: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68:2581-2586, 2008 (Pubitemid 351556255)
31. Konstantinopoulos PA, Fountzilas E, Pillay K, et al: Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics 1:59, 2008
32. Radmacher MD, McShane LM, Simon R: A paradigm for class prediction using gene expression profiles. J Comput Biol 9:505-511, 2002 (Pubitemid 34920572)
33. Dabney AR: Classification of microarrays to nearest centroids. Bioinformatics 21:4148-4154, 2005
34. Dabney AR, Storey JD: Optimality driven nearest centroid classification from genomic data. PLoS One 2:e1002, 2007
35. Chang CC, Lin CJ: Training nu-support vector classifiers: Theory and algorithms. Neural Comput 13:2119-2147, 2001
36. Edwards SL, Brough R, Lord CJ, et al: Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-1115, 2008 (Pubitemid 351317441)
37. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002 (Pubitemid 34260526)
38. Shattuck-Eidens D, Oliphant A, McClure M, et al: BRCA1 sequence analysis in women at high risk for susceptibility mutations: Risk factor analysis and implications for genetic testing. JAMA 278:1242-1250, 1997 (Pubitemid 27435611)
39. Quinn JE, James CR, Stewart GE, et al: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13:7413-7420, 2007
40. Freitas S, Moore DH, Michael H, et al: Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: Correlations with tumor progression and platinum resistance. Clin Cancer Res 9:4689-4694, 2003 (Pubitemid 37323270)
41. Mol CD, Hosfield DJ, Tainer JA: Abasic site recognition by two apurinic/apyrimidinic endonuclease families in DNA base excision repair: The 3′ ends justify the means. Mutat Res 460:211-229, 2000 (Pubitemid 30628592)
42. Godwin AK, Meister A, O'Dwyer PJ, et al: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 89:3070-3074, 1992
43. Johnson SW, Ozols RF, Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer 71:644-649, 1993 (Pubitemid 23021264)
44. Aebi S, Kurdi-Haidar B, Gordon R, et al: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087-3090, 1996 (Pubitemid 26199755)
45. Durant ST, Morris MM, Illand M, et al: Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol 9:51-54, 1999 (Pubitemid 29045795)
46. Ryan PD, Tung NM, Isakoff SJ, et al: Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. J Clin Oncol 27:18s, 2009 (suppl; abstr 551)